Bio-Rad Laboratories (NYSE:BIO) EVP Sells $214,326.00 in Stock

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP James Barry sold 700 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the sale, the executive vice president owned 510 shares in the company, valued at approximately $156,151.80. The trade was a 57.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Bio-Rad Laboratories Stock Up 0.7%

Shares of Bio-Rad Laboratories stock traded up $2.09 during trading on Monday, reaching $307.65. 116,462 shares of the company traded hands, compared to its average volume of 304,748. The firm has a market capitalization of $8.33 billion, a PE ratio of -12.66 and a beta of 1.04. Bio-Rad Laboratories, Inc. has a 1-year low of $211.43 and a 1-year high of $373.69. The company has a 50 day moving average price of $300.02 and a 200-day moving average price of $267.73. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a positive return on equity of 4.18% and a negative net margin of 26.43%.The firm had revenue of $653.00 million for the quarter, compared to analyst estimates of $651.30 million. During the same period last year, the company posted $2.01 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. TD Asset Management Inc increased its position in shares of Bio-Rad Laboratories by 461.0% in the third quarter. TD Asset Management Inc now owns 8,988 shares of the medical research company’s stock valued at $2,520,000 after acquiring an additional 7,386 shares during the period. OneDigital Investment Advisors LLC lifted its holdings in Bio-Rad Laboratories by 1.9% in the third quarter. OneDigital Investment Advisors LLC now owns 2,954 shares of the medical research company’s stock worth $828,000 after buying an additional 55 shares during the period. Silver Oak Advisory Group Inc. bought a new stake in shares of Bio-Rad Laboratories during the third quarter valued at approximately $203,000. JPMorgan Chase & Co. raised its holdings in Bio-Rad Laboratories by 4.7% in the third quarter. JPMorgan Chase & Co. now owns 56,250 shares of the medical research company’s stock worth $15,772,000 after purchasing an additional 2,519 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Bio-Rad Laboratories by 3.3% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,104 shares of the medical research company’s stock worth $870,000 after buying an additional 98 shares during the period. 65.24% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

BIO has been the topic of a number of research reports. Weiss Ratings raised shares of Bio-Rad Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, October 30th. Royal Bank Of Canada upped their price objective on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, November 1st. Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Finally, Wells Fargo & Company lifted their price target on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Three research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $358.50.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.